Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BWG, Compérat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64:639–53.
Article
PubMed
Google Scholar
Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71:96–108.
Article
PubMed
Google Scholar
Ploeg M, Aben KKH, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27:289–93.
Article
PubMed
PubMed Central
Google Scholar
Johnson DC, Greene PS, Nielsen ME. Surgical advances in bladder cancer: at what cost? Urol Clin North Am. 2015;42:235–52. ix
Article
PubMed
Google Scholar
Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A, et al. ESMO practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii40–8.
Article
PubMed
Google Scholar
van Rhijn BWG, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56:430–42.
Article
PubMed
Google Scholar
Rouprêt M, Neuzillet Y, Masson-Lecomte A, Colin P, Compérat E, Dubosq F, et al. CCAFU french national guidelines 2016-2018 on bladder cancer. Progres En Urol. 2016;27(Suppl 1):S67–91.
Article
Google Scholar
Bellmunt J, Albiol S. Chemotherapy for metastatic or unresectable bladder cancer. Semin Oncol. 2007;34:135–44.
Article
CAS
PubMed
Google Scholar
Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27:4454–61.
Article
CAS
PubMed
Google Scholar
Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558–62.
Article
CAS
PubMed
Google Scholar
Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909–20.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee J-L, Fong L, et al. Pembrolizumab as second-line therapy for advanced Urothelial carcinoma. N Engl J Med. 2017;376:1015–26.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312–22.
Article
CAS
PubMed
Google Scholar
Hahn NM, Powles T, Massard C, Arkenau H-T, Friedlander TW, Hoimes CJ, et al. Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC). J Clin Oncol. 2017;35:4525.
Google Scholar
Patel MR, Ellerton JA, Infante JR, Agrawal M, Gordon MS, Aljumalyi R, et al. Avelumab in patients with metastatic urothelial carcinoma: pooled results from two cohorts of the phase 1b JAVELIN solid tumor trial. J Clin Oncol. 2017;35:330.
Article
Google Scholar
Houédé N, Pourquier P. Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers. Pharmacol Ther. 2015;145:1–18.
Article
PubMed
Google Scholar
Fechner G, Classen K, Schmidt D, Hauser S, Müller SC. Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer. Urology. 2009;73:665–9.
Article
PubMed
Google Scholar
Schedel F, Pries R, Thode B, Wollmann B, Wulff S, Jocham D, et al. mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma. Oncol Rep. 2011;25:763–8.
CAS
PubMed
Google Scholar
Mansure JJ, Nassim R, Chevalier S, Rocha J, Scarlata E, Kassouf W. Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol Ther. 2009;8:2339–47.
Article
CAS
PubMed
Google Scholar
Vasconcelos-Nóbrega C, Pinto-Leite R, Arantes-Rodrigues R, Ferreira R, Brochado P, Cardoso ML, et al. In vivo and in vitro effects of RAD001 on bladder cancer. Urol Oncol. 2013;31:1212–21.
Article
PubMed
Google Scholar
Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381:125–32.
Article
CAS
PubMed
Google Scholar
Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32:760–7.
Article
CAS
PubMed
Google Scholar
Rini BI, Bellmunt J, Clancy J, Wang K, Niethammer AG, Hariharan S, et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol. 2014;32:752–9.
Article
CAS
PubMed
Google Scholar
Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520–9.
Article
CAS
PubMed
Google Scholar
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–23.
Article
CAS
PubMed
PubMed Central
Google Scholar
Seront E, Rottey S, Sautois B, Kerger J, D’Hondt LA, Verschaeve V, et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol. 2012;23:2663–70.
Article
CAS
PubMed
Google Scholar
Milowsky MI, Iyer G, Regazzi AM, Al-Ahmadie H, Gerst SR, Ostrovnaya I, et al. Phase II study of everolimus in metastatic urothelial cancer. BJU Int. 2013;112:462–70.
Article
CAS
PubMed
PubMed Central
Google Scholar
Iyer G, Al-Ahmadie H, Schultz N, Hanrahan AJ, Ostrovnaya I, Balar AV, et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol. 2013;31:3133–40.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gerullis H, Eimer C, Ecke TH, Georgas E, Freitas C, Kastenholz S, et al. A phase II trial of temsirolimus in second-line metastatic urothelial cancer. Med Oncol. 2012;29:2870–6.
Article
CAS
PubMed
Google Scholar
Houédé N, Roubaud G, Mahammedi H, Vedrine L, Joly F, Mourey L, et al. Safety and efficacy of temsirolimus as second-line treatment for patients with recurrent bladder cancer. J Clin Oncol. 2015;33(suppl 7):abstr 304.
Article
Google Scholar
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
Article
CAS
PubMed
Google Scholar
Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10.
Article
CAS
PubMed
Google Scholar
Machin D, Campbell MJ, Tan S-B, Tan S-H. Sample size tables for clinical studies. 3rd ed. Chicester: Wiley; 2009.
Costa C, Pereira S, Lima L, Peixoto A, Fernandes E, Neves D, et al. Role in bladder cancer prognosis and targeted therapeutics. PLoS One. 2015;10:e0141253.
Article
PubMed
PubMed Central
Google Scholar
Bellmunt J, Kerst JM, Vázquez F, Morales-Barrera R, Grande E, Medina A, et al. A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN). Ann Oncol. 2017;28:1517–22.
Article
CAS
PubMed
Google Scholar
Seront E, Rottey S, Filleul B, Glorieux P, Goeminne J-C, Verschaeve V, et al. Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma. BJU Int. 2016;118:408–15.
Article
CAS
PubMed
Google Scholar
Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338:221.
Article
CAS
PubMed
PubMed Central
Google Scholar
Öztürk H. Comparing RECIST with EORTC criteria in metastatic bladder cancer. J Cancer Res Clin Oncol. 2016;142:187–94.
Article
PubMed
Google Scholar
Gupta S, Gill D, Poole A, Agarwal N. Systemic immunotherapy for Urothelial cancer: current trends and future directions. Cancers. 2017;9:pii:E15.
Article
Google Scholar
Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12:237–51.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hau AM, Nakasaki M, Nakashima K, Krish G, Hansel DE. Differential mTOR pathway profiles in bladder cancer cell line subtypes to predict sensitivity to mTOR inhibition. Urol Oncol. 2017;35:593–9.
Article
CAS
PubMed
Google Scholar